Q3 2024 Swedish Orphan Biovitrum AB (publ) Earnings Call Transcript
Key Points
- Swedish Orphan Biovitrum AB (BIOVF) reported a significant top-line growth of 39% in Q3 2024.
- The company achieved an adjusted EBITDA margin of 43% for the quarter, reflecting strong financial performance.
- Hematology and immunology sales drove the growth, with immunology sales increasing by 96%.
- The strategic growth portfolio contributed 56% of total business, growing by 113% in Q3.
- Positive clinical trial results, such as a 68% reduction in proteinuria for Aspaveli in nephrology, highlight promising pipeline developments.
- The company anticipates a slowdown in growth in Q4 2024 due to challenging comparisons from the previous year.
- There is continued price pressure in many regions, affecting the overall financial performance.
- The launch of Vonjo faced internal challenges and competition, impacting its market performance.
- The company expects continued elevated spending in R&D and SG&A, which could affect profitability.
- There are concerns about the impact of new competitors on market share and pricing pressure for key products.
()- -
Yeah, thank you so much and welcome everybody. This is Guido Oelkers CEO of SOBI, so we are delighted to welcome you to the third quarter, 2024 conference call for investors and analysts. We posted this presentation earlier today under sobi.com.
Please turn to page number two. And as per usual forward-looking statement, please take note of it and unless stated otherwise, we are making comments that most relate to the third quarter at constant exchange rate in millions of Swedish kronor.
Today, we plan to cover the key aspects of the Q3 report.
I'm joined by Henrik Stenqvist, our CFO Lydia Abad-Franch, Head of R&D and Chief Medical Officer and during the Q&A session by Armin Reininger our Senior Scientific Adviser, we plan to review the during the presentation first and then cover Q&A thereafter. And this session will take around, we'll take until 3 p.m. for those on the phone. As as usual, please join the queue for question and by pressing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
